Investment to Accelerate Commercialization of Lung Cancer Test in China
The funds will support 20/20’s efforts to customize for the Chinese market its proprietary algorithm for blood biomarker testing for cancer. The algorithm will then be made available to hundreds of hospitals and Health Check centers throughout China using a cloud based software-as-a-service (SaaS) model. “We look forward to making a large impact in helping to reduce lung cancer mortality in China, among the highest in the world due to very high smoking prevalence and air pollution,” said Jonathan Cohen, 20/20’s CEO. “Beyond China, we plan to rapidly introduce our novel technology in other Asian nations, Europe, and the U.S.  Ping An, as a major provider of health insurance in China, will be an extremely important strategic partner in this effort.”

Read the whole release